E-ISSN 2231-3206 | ISSN 2320-4672
 

Original Research 


Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients

Mounika Vasa, Madhukar Rao Polasani, Ravi D Mala, Anurag Yadav, Patil Banderao Venkatrao.

Abstract
Background: The common cause of mortality in India is related to complications of cardiovascular disease which has direct relation with the hyperlipidemia, diabetes mellitus, and hypertension. Rosuvastatin more efficacious than other statins in lesser dosage and having good safety profile.

Aim and Objective: The present study was undertaken to evaluate the safety, efficacy of rosuvastatin 10 mg daily dose versus alternate day dose in hyperlipidemia patients.

Materials and Methods: A total of 50 individuals with hyperlipidemia were selected in this prospective open label research. Patients were grouped as Group D with rosuvastatin daily dose and Group A with alternate day dose. Fasting plasma lipid profile was assessed in both groups on the 1st, 4th, and 6th weeks.

Results: There is significant reduction in total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and elevation of high-density lipoprotein (HDL) after 4 weeks and 6 weeks of the treatment in both the groups compared to baseline. The mean percentage reduction of total cholesterol was by 24% and 21.60% (P < 0.05) in Group D and Group A, respectively. The mean percentage reduction of LDL-C was by 33.50% and 31% (P < 0.05) Group D and Group A, respectively. The mean percentage improvement of HDL-cholesterol was by 19.89% and 17.09% (P < 0.05) in Group D and Group A, respectively. The mean percentage of reduction of TG was by 36.70% and 41.33% (P < 0.05) Group D and Group A.

Conclusion: Rosuvastatin 10 mg on alternate days had the same efficacy in lowering cholesterol levels as taking it every day, also it may be a cost-effective alternative without sacrificing therapeutic benefits or side effects.

Key words: Rosuvastatin; Cholesterol; Cost-effective; Safety; Hyperlipidemia


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Mounika Vasa
Articles by Madhukar Rao Polasani
Articles by Ravi D Mala
Articles by Anurag Yadav
Articles by Patil Banderao Venkatrao
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Vasa M, Polasani MR, Mala RD, Yadav A, Venkatrao PB. Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients. Natl J Physiol Pharm Pharmacol. 2023; 13(1): 21-26. doi:10.5455/njppp.2023.13.03115202218052022


Web Style

Vasa M, Polasani MR, Mala RD, Yadav A, Venkatrao PB. Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients. https://www.njppp.com/?mno=100051 [Access: February 01, 2023]. doi:10.5455/njppp.2023.13.03115202218052022


AMA (American Medical Association) Style

Vasa M, Polasani MR, Mala RD, Yadav A, Venkatrao PB. Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients. Natl J Physiol Pharm Pharmacol. 2023; 13(1): 21-26. doi:10.5455/njppp.2023.13.03115202218052022



Vancouver/ICMJE Style

Vasa M, Polasani MR, Mala RD, Yadav A, Venkatrao PB. Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients. Natl J Physiol Pharm Pharmacol. (2023), [cited February 01, 2023]; 13(1): 21-26. doi:10.5455/njppp.2023.13.03115202218052022



Harvard Style

Vasa, M., Polasani, . M. R., Mala, . R. D., Yadav, . A. & Venkatrao, . P. B. (2023) Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients. Natl J Physiol Pharm Pharmacol, 13 (1), 21-26. doi:10.5455/njppp.2023.13.03115202218052022



Turabian Style

Vasa, Mounika, Madhukar Rao Polasani, Ravi D Mala, Anurag Yadav, and Patil Banderao Venkatrao. 2023. Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients. National Journal of Physiology, Pharmacy and Pharmacology, 13 (1), 21-26. doi:10.5455/njppp.2023.13.03115202218052022



Chicago Style

Vasa, Mounika, Madhukar Rao Polasani, Ravi D Mala, Anurag Yadav, and Patil Banderao Venkatrao. "Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients." National Journal of Physiology, Pharmacy and Pharmacology 13 (2023), 21-26. doi:10.5455/njppp.2023.13.03115202218052022



MLA (The Modern Language Association) Style

Vasa, Mounika, Madhukar Rao Polasani, Ravi D Mala, Anurag Yadav, and Patil Banderao Venkatrao. "Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients." National Journal of Physiology, Pharmacy and Pharmacology 13.1 (2023), 21-26. Print. doi:10.5455/njppp.2023.13.03115202218052022



APA (American Psychological Association) Style

Vasa, M., Polasani, . M. R., Mala, . R. D., Yadav, . A. & Venkatrao, . P. B. (2023) Evaluation of the therapeutic benefits of single daily dose versus alternate day dose of rosuvastatin in hyperlipidemia patients. National Journal of Physiology, Pharmacy and Pharmacology, 13 (1), 21-26. doi:10.5455/njppp.2023.13.03115202218052022